S. Sagheer, S. Rodgers, O. Yacoub, R. Dauer, S. Mcrae et al., Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and

, HemosIL LIA assay with ristocetin cofactor assay by aggregometry, Haemophilia, vol.22, pp.200-207, 2016.

M. Stockschlaeder, R. Schneppenheim, and U. Budde, Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis, Blood Coagul Fibrinolysis, vol.25, pp.206-222, 2014.

H. J. Weiss, L. W. Hoyer, F. R. Rickles, A. Varma, and J. Rogers, Quantitative Assay of a Plasma Factor Deficient in von Willebrand's Disease that is Necessary for Platelet Aggregation. RELATIONSHIP TO FACTOR VIII PROCOAGULANT ACTIVITY AND ANTIGEN CONTENT, J Clin Invest, vol.52, pp.2708-2724, 1973.

J. E. Sadler, U. Budde, J. Eikenboom, E. J. Favaloro, F. Hill et al.,

, Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor, J Thromb Haemost, vol.4, pp.2103-2117, 2006.

M. Furlan, Von Willebrand factor: molecular size and functional activity, Ann Hematol, vol.72, pp.341-349, 1996.

. Wagner, Induction of Specific Storage Organelles by van Willebrand Factor Propolypeptide. Cell, 1991.

Z. M. Ruggeri, F. I. Pareti, P. M. Mannucci, N. Ciavarella, and T. S. Zimmerman, Heightened Interaction between Platelets and Factor VIII/von Willebrand Factor in a New Subtype of von Willebrand's Disease, N Engl J Med, vol.302, pp.1047-51, 1980.

E. J. Favaloro, Rethinking the diagnosis of von Willebrand disease, Thromb Res, vol.127, pp.17-21, 2011.

S. Kumar, R. K. Pruthi, and W. L. Nichols, Acquired von Willebrand Disease, Mayo Clin Proc, vol.77, pp.181-188, 2002.

A. Federici, J. Rand, P. Bucciarelli, U. Budde, P. Van-genderen et al., Acquired von Willebrand Syndrome: Data from an International Registry: On behalf of the Subcommittee on von Willebrand Factor, Thromb Haemost, vol.84, pp.345-354, 2000.

. Sanchez-luceros, Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases. Haematologica, 2002.

A. Rottenstreich, G. Kleinstern, S. Krichevsky, D. Varon, D. Lavie et al., Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera, Eur J Intern Med, vol.41, pp.49-54, 2017.

A. B. Federici, Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?, J Thromb Haemost, vol.6, pp.565-573, 2008.

P. Collins, U. Budde, J. H. Rand, A. B. Federici, and C. M. Kessler, Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome, Haemophilia, vol.14, pp.49-55, 2008.

A. Tefferi and T. Barbui, Personalized management of essential thrombocythemia-application of recent evidence to clinical practice, Leukemia, vol.27, pp.1617-1637, 2013.

A. Tefferi and T. Barbui, Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management: Polycythemia vera and essential thrombocythemia, Am J Hematol, vol.90, pp.162-73, 2015.

A. Tiede, J. H. Rand, U. Budde, A. Ganser, and A. B. Federici, How I treat the acquired von Willebrand syndrome, Blood, vol.117, pp.6777-85, 2011.

J. J. Michiels, U. Budde, M. Van-der-planken, H. Van-vliet, W. Schroyens et al., Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management, Best Pract Res Clin Haematol, vol.14, pp.401-437, 2001.

C. James, V. Ugo, N. Casadevall, S. N. Constantinescu, and W. Vainchenker, A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects, Trends Mol Med, vol.11, pp.546-54, 2005.

T. Rungjirajittranon, W. Owattanapanich, P. Ungprasert, N. Siritanaratkul, and T. Ruchutrakool, A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms, BMC Cancer, vol.19, p.184, 2019.

M. Hultcrantz, M. Björkholm, P. W. Dickman, O. Landgren, Å. R. Derolf et al., Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study, Ann Intern Med, vol.168, p.317, 2018.

G. Finazzi, A. Carobbio, J. Thiele, F. Passamonti, E. Rumi et al., Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria, Leukemia, vol.26, pp.716-725, 2012.

A. Kaifie, M. Kirschner, D. Wolf, C. Maintz, M. Hänel et al., Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry, J Hematol OncolJ Hematol Oncol, vol.9, p.18, 2016.

A. Carobbio, A. Ferrari, A. Masciulli, A. Ghirardi, G. Barosi et al., Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis, Blood Adv, vol.3, pp.1729-1766, 2019.

B. L. Stein and K. Martin, From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms, p.10

T. Rungjirajittranon, W. Owattanapanich, P. Ungprasert, N. Siritanaratkul, and T. Ruchutrakool, A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms, BMC Cancer, vol.19, p.184, 2019.

P. J. Campbell, C. Maclean, P. A. Beer, G. Buck, K. Wheatley et al., Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort, Blood, vol.120, pp.1409-1420, 2012.

C. Jenkis, D. R. Philmips, K. J. Clemmorson, D. Meyer, M. Larrieu et al., Platelet Membrane Glycoproteins Implicated in Ristocetin-Induced Aggregation

A. Rottenstreich, G. Kleinstern, S. Krichevsky, D. Varon, D. Lavie et al., Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera, Eur J Intern Med, vol.41, pp.49-54, 2017.

S. Sagheer, S. Rodgers, O. Yacoub, R. Dauer, S. Mcrae et al., Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and

, HemosIL LIA assay with ristocetin cofactor assay by aggregometry, Haemophilia, vol.22, pp.200-207, 2016.

A. Rottenstreich, G. Kleinstern, S. Krichevsky, D. Varon, D. Lavie et al., Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera, Eur J Intern Med, vol.41, pp.49-54, 2017.

S. Sagheer, S. Rodgers, O. Yacoub, R. Dauer, S. Mcrae et al., Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and

, HemosIL LIA assay with ristocetin cofactor assay by aggregometry, Haemophilia, vol.22, pp.200-207, 2016.

F. Stufano, L. Baronciani, M. T. Pagliari, F. Franchi, G. Cozzi et al., Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination, J Thromb Haemost, vol.13, pp.1806-1820, 2015.

A. S. Lawrie, F. Stufano, M. T. Canciani, I. J. Mackie, S. J. Machin et al., A comparative evaluation of a new automated assay for von Willebrand factor activity, Haemophilia, vol.19, pp.338-380, 2013.